Our next aim was to determine whether the FCBA BCR-ABL1 could substitute for FISH analysis in follow-up of CML patients within the first year of TKI therapy to monitor early achievement of a cytogenetic response. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.